Loading…

Comparison of high intensity focused ultrasound and radioiodine for treating toxic thyroid nodules

Summary Purpose We compared the effectiveness of high intensity focused ultrasound (HIFU) and radioiodine (RAI) to treat patients carrying toxic thyroid nodule (TTN). Normalization of serum thyrotropin (TSH) 1 year after treatment was the primary end‐point; concurrent changes in nodules' volume...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 2018-08, Vol.89 (2), p.219-225
Main Authors: Giovanella, Luca, Piccardo, Arnoldo, Pezzoli, Cinzia, Bini, Fabiano, Ricci, Riccardo, Ruberto, Teresa, Trimboli, Pierpaolo
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Purpose We compared the effectiveness of high intensity focused ultrasound (HIFU) and radioiodine (RAI) to treat patients carrying toxic thyroid nodule (TTN). Normalization of serum thyrotropin (TSH) 1 year after treatment was the primary end‐point; concurrent changes in nodules' volume and scintigraphic pattern were also evaluated as secondary end‐points. Materials and Methods Among patients ≥18 years old with TTN observed at our centre between January 1st, 2016 and December 31th, 2016 we prospectively enrolled 17 and 15 age and sex‐matched patients treated with RAI and HIFU, respectively. Biochemical thyroid tests and nodules' volume were assessed before and 3, 6 and 12 months after treatments. A thyroid scintigraphy was performed before and 1 year after treatment, respectively. Results The final series included 17 patients treated with RAI and 15 patients treated with HIFU, respectively. Neither demographic nor clinical differences were found at baseline. One year after treatment 14 of 17 RAI‐treated and 4 of 15 HIFU‐treated patients fulfilled criteria for response to treatment (P = .0008). Indeed, the median TSH value was 1.5 IU/mL and 0.2 IU/mL in HIFU and RAI groups, respectively (P 
ISSN:0300-0664
1365-2265
DOI:10.1111/cen.13738